Kymriah (tisagenlecleucel-T) / University of Pennsylvania, Novartis - LARVOL DELTA

Real-world incidence of HLH-like syndromes across CAR T-cell products: A multi-institutional cohort study using the trinetx network (ASH 2025) - "Adult patients (aged ≥18 years) who received one of four U.S. Food and Drug Administration-approved CAR T-cell therapies—axicabtagene ciloleucel (Axi-cel), tisagenlecleucel (Tisa-cel), lisocabtagene maraleucel (Liso-cel), or idecabtagene vicleucel (Ide-cel) between 2017 and 2024 were included. In this large, multi-institutional real-world study, HLH-like syndromes were observed following all CAR T-cell products, with notable variation in incidence by agent. Idecabtagene vicleucel and tisagenlecleucel were associated with the highest 30-day HLH incidence, while axicabtagene ciloleucel had the lowest. These findings highlight the need for product-specific clinical vigilance and may inform post-infusion monitoring protocols."

CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • Hemophagocytic lymphohistiocytosis • Immunology • Inflammation • Rare Diseases

Efficacy and safety of CAR-t cell therapy in richter transformation: A systematic review (ASH 2025) - "Lymphodepletion regimens included fludarabine/cyclophosphamide (FC) or bendamustine. CAR-T products administered were axi-cel (n=148), tisa-cel (n=131), liso-cel (n=57), brexu-cel (n=1), and investigational agents (n=29)... CAR-T therapy shows promising initial responses in RT, with ORR and CR rates comparable to de novo DLBCL. However, responses are often short-lived, with inferior PFS and OS compared to outcomes in aggressive lymphoma trials. RT patients face higher toxicity—particularly ICANS, cytopenias, and infections—reflecting disease biology and prior treatments."

CAR T-Cell Therapy • Clinical • IO biomarker • Review • B Cell Lymphoma • Chronic Lymphocytic Leukemia • CNS Disorders • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Richter's Syndrome • Thrombocytopenia • IGH • TP53

Comparative safety profiles of bispecific T-cell engagers and CAR-T therapies: Real-world insights from the FDA adverse event reporting system database (ASH 2025) - "BiTEs demonstrated a significantly higher disproportionality signal for neutropenia compared to CAR-T therapies (PRR=1.74, ROR=1.93, 95% CI [1.89, 1.98], p<0.001), with Glofitamab showing the highest reporting rate (42.2%) among BiTEs...Tisagenlecleucel had the highest hepatotoxicity rate (4.1%) among CAR-T agents...Axicabtagene ciloleucel had the highest venous thrombosis rate (42.6%) among CAR-T agents...Brexucabtagene autoleucel had the highest rate of arterial thrombosis (0.78%) among CAR-T agents. This real-world analysis reinforces the well-characterized neurotoxicity associated with CAR-T therapies, while highlighting the higher rate of neutropenia with BiTEs. These distinct toxicity profiles emphasize the importance of individualized treatment selection, considering patient comorbidities, toxicity tolerance, logistical factors, and the clinical context, which includes the potential for better disease control with specific therapies."

Adverse events • Clinical • Real-world • Real-world evidence • Acute Kidney Injury • Cardiovascular • Hematological Malignancies • Hepatology • Nephrology • Neutropenia • Renal Disease • Thrombosis • ROR1

Incidence of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), infections and cardiovascular events across different chimeric antigen receptor (CAR) T-cell therapy products in large B-cell lymphoma (DLBCL): A nationwide analysis (ASH 2025) - "Three CAR T-cell products have received approval: axicabtagene ciloleucel (Yescarta), lisocabtagene maraleucel (Breyanzi), and tisagenlecleucel (Kymriah). The limitations of our study include its retrospective nature, reliance on ICD-10 codes to identify patients with adverse events, and the absence of longitudinal data on long-term adverse events. Nevertheless, this study provides essential insights for hematologists regarding the incidence of specific adverse events associated with different CAR T-cell products within the real-world population."

Cytokine release syndrome • B Cell Lymphoma • Cardiovascular • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Myocardial Infarction • Non-Hodgkin’s Lymphoma • Pneumonia • Respiratory Diseases • Septic Shock

Analysis of the cost-effectiveness without compromising clinical outcomes in outpatient CD19-directed CAR-T therapy in non-Hodgkin lymphoma patients at a community-based medical center (ASH 2025) - "Secondary objectives included assessment of toxicity, response, and survival in patients receiving axicabtagene ciloleucel (axi-cel), brexucabtagene autoleucel (brexu-cel), lisocabtagene maraleucel (liso-cel), or tisagenlecleucel (tisa-cel)...In 2024, one patient received prophylactic dexamethasone prior to infusion... Based on CMS data and the ZUMA-1 trial, the median inpatient stay for CAR-T therapy is approximately 15 days, with Medicare reimbursing an average of $498,700 per admission. This includes the high cost of the CAR-T product and the intensive inpatient care needed to manage toxicities like CRS and ICANS. In contrast, a typical 7-day inpatient hospital stay costs Medicare only $13,000 to $18,000."

Clinical • Clinical data • Cost effectiveness • HEOR • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Nodal Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma

Platelet decrease and efficacy of platelet-rich plasma return for CAR-T lymphocyte apheresis in low-weight patients (ASH 2025) - "Notably, tisagenlecleucel (Tisa-cel) requires the collection of a defined absolute number of CD3-positive T cells rather than a fixed processed volume, which often necessitates larger blood processing volumes in lower-weight patients and may further increase the risk of platelet loss...Collectively, our data suggest that CAR-T lymphocyte apheresis in low-weight patients can cause substantial thrombocytopenia, and that PRP return may serve as a beneficial strategy to attenuate this effect, though it does not fully restore pre-apheresis platelet levels. Furthermore, body weight and processed blood volume per kilogram emerged as key risk factors, underscoring the need for individualized blood volume estimation and standardized apheresis protocols tailored to this vulnerable population."

Clinical • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Thrombocytopenia

Aberrant lymphocytes are associated with increased inflammatory complications following CAR-T infusion (ASH 2025) - "CAR-T products included axi-cel (Yescarta) (n=10), brexu-cel (Tecartus) (n=2), liso-cel (Breyanzi) (n=1), tisa-cel (Kymriah) (n=1), or CD19-Car_Lenti (produced by the Officina Farmaceutica of Bambino Gesù Children's Hospital) (n=2)...Associations were not found between number of aberrant lymphocytes and development of neurotoxicity (eg, ICANS) nor with doses of Tocilizumab, Dexamethasone, or Anakinra or with WBC. While the number of patients is small, presence of increased aberrant lymphocytes, as pre-classified by the Scopio full-field digital morphology platform, appears to be associated with increased inflammatory complications following CAR-T infusion, including CRS of grade ≥2 and prolonged neutropenia requiring G-CSF support. Digital morphology combined with artificial intelligence may represent a novel platform for predicting clinical outcomes in CAR-T therapy."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Rheumatology

Comparative efficacy and safety of bendamustine versus fludarabine and cyclophosphamide as lymphodepleting regimens for CAR-T therapy in hematological malignancies: A systematic review and meta-analysis (ASH 2025) - "Axicabtagene ciloleucel was used in four studies, brexucabtagene autoleucel and tisagenlecleucel in two studies, and lisocabtagene maraleucel, idecabtagene vicleucel, and ciltacabtagene autoleucel in one study each. These findings suggest that bendamustine may serve as a viable alternative LD regimen, especially for patients at high risk of infections. Further prospective studies are warranted to confirm the safety and efficacy of bendamustine compared to standard FluCy regimen."

Retrospective data • Review • Acute Lymphocytic Leukemia • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology

Incidence and outcomes of Clostridioides difficile infection in BCMA and CD19 CAR-T cell therapy. (ASH 2025) - "Among individual CAR-T products, the incidence was: for CD19-directed CAR-T, Brexu-cel 5%, Axi-cel 6%, Tisa-cel 5%, and Liso-cel 3%; for BCMA-directed CAR-T, Ide-cel 4% and Cilta-cel 5%. In patients with hematologic malignancies, identifying risk factors and rates of CDI in CAR-T cell therapy is essential for prompt recognition and effective management. Future research on optimizing CDI screening protocol and prevention strategies can help reduce mortality and morbidity in this immunocompromised population."

CAR T-Cell Therapy • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma

Impact of pulmonary and cardiac comorbidities on cytokine release syndrome incidence in chimeric antigen receptor (CAR) t-treated diffuse large B-cell lymphoma (DLBCL) patients: A real-world data analysis (ASH 2025) - "All patients received CAR–T–cell therapy with either tisagenlecleucel, lisocabtagene maraleucel, or axicabtagene ciloleucel. This real-world analysis demonstrates that DLBCL patients with pre-existing pulmonary and/or cardiac comorbidities have a significantly higher risk of developing CRS following CAR T-cell therapy compared to those without such comorbidities. Interestingly, despite the increased incidence of CRS, the presence of these comorbidities did not significantly impact short-term overall survival among patients who developed CRS. These findings underscore the importance of careful patient selection and vigilant monitoring for CRS in DLBCL patients with pulmonary and/or cardiac comorbidities undergoing CAR T-cell therapy."

Clinical • Cytokine release syndrome • Real-world • Real-world evidence • Asthma • Atherosclerosis • B Cell Lymphoma • Cardiovascular • Chronic Obstructive Pulmonary Disease • Diffuse Large B Cell Lymphoma • Heart Failure • Hematological Malignancies • Hypertension • Immunology • Inflammation • Lymphoma • Non-Hodgkin’s Lymphoma • Obstructive Sleep Apnea • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • Sinusitis • Sleep Apnea • Sleep Disorder • Systemic Inflammatory Response Syndrome

Real-world patterns of secondary malignancies and relapse following CAR T-cell therapy: A faers pharmacovigilance analysis (ASH 2025) - "Six CAR T-cell products have been approved by the U.S. Food and Drug Administration (FDA) to date: tisagenlecleucel (Tisa-cel), axicabtagene ciloleucel (Axi-cel), brexucabtagene autoleucel (Brexu-cel), lisocabtagene maraleucel (Liso-cel), ciltacabtagene autoleucel (Cilta-cel), and idecabtagene vicleucel (Ida-cel), for pediatric and adult B-cell acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), multiple myeloma, follicular lymphoma and mantle cell lymphoma. Our FAERS analysis reveals distinct patterns of secondary primary malignancies and relapsed diseases following CAR T-cell therapy in real-world settings. The identification of myelodysplastic syndromes, cutaneous neoplasms, and rare T-cell or solid tumors highlights the need for vigilant post-therapy surveillance."

Adverse events • CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Basal Cell Carcinoma • Brain Cancer • Carcinoid Tumor • Diffuse Large B Cell Lymphoma • Endocrine Cancer • Eye Cancer • Follicular Lymphoma • Gastric Cancer • Glioblastoma • Glioneuronal Tumor • Head and Neck Cancer • Hematological Malignancies • Kaposi Sarcoma • Leiomyosarcoma • Leukemia • Lung Cancer • Lymphoma • Mantle Cell Lymphoma • Merkel Cell Carcinoma • Multiple Myeloma • Myelodysplastic Syndrome • Neuroendocrine Carcinoma • Non-Hodgkin’s Lymphoma • Non-melanoma Skin Cancer • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Peripheral T-cell Lymphoma • Rhabdomyosarcoma • Sarcoma • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Squamous Cell Skin Cancer • T Cell Non-Hodgkin Lymphoma

Tocilizumab prophylaxis in patients receiving CAR-T cell immunotherapy for hematological malignancies: A systematic review and meta-analysis (ASH 2025) - "Four studies examining 91 patients with hematological malignancies (B-cell non-Hodgkin lymphomas: 76, ALL: 6, in 9 not specified) receiving tocilizumab prophylaxis (1 dose, 8 mg/kg) before CAR-T therapy (Axicabtagene ciloleucel: 38, Tisagenlecleucel: 2, other CD19-CAR-T cell products: 43, in 8 not specified) were included in the qualitative analysis. Based on these data, tocilizumab prophylaxis prior to infusion in patients who receive CAR-T cell immunotherapy can significantly decrease the risk of both any grade and grade >2 CRS. ICANS incidence was similar to ongoing published data and more than half of patients receiving tocilizumab prophylaxis achieved PFS. The need for larger, randomized controlled trials to confirm the observed effects and determine the impact of prophylactic tocilizumab on OS, TRM, adverse events, and infectious complications is warranted."

CAR T-Cell Therapy • Retrospective data • Review • Acute Lymphocytic Leukemia • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • IL6

Endocrine adverse events following CAR-T cell therapies: A pharmacovigilance analysis in the real-world setting utilizing the faers database (ASH 2025) - "CAR-T products analyzed included axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel, ciltacabtagene autoleucel, idecabtagene vicleucel, and lisocabtagene maraleucel. This FAERS-based real-world analysis identifies relevant endocrine toxicities linked to CAR-T therapies, with strongest associations observed for axicabtagene ciloleucel and tisagenlecleucel. Immune-mediated dysfunction in the pituitary and thyroid axes appears most prominent. These findings support the need for increased endocrine monitoring post-CAR-T and suggest a class-wide effect with further prospective study."

Adverse events • CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • Cushing’s Disease • Diabetes • Endocrine Disorders • Hematological Malignancies • Immunology • Metabolic Disorders • Nephrology • Renal Disease

Comparative analysis of CAR-T cell therapies across lymphoma subtypes: Efficacy, safety, and future perspectives (ASH 2025) - "Toxicity varied by costimulatory domain: CD28-based constructs (axi-cel) were associated with higher rates of CRS and immune effector cell-associated neurotoxicity syndrome than 4-1BB-based (costimulatorydomain) constructs (liso-cel, tisa-cel)...In mantle cell lymphoma (MCL), brexucabtagene autoleucel reduced or eliminated cancer in 93% of patients, with complete disappearance seen in 67%... C AR-T therapy offers subtype-specific advantages, with FL showing higher response rates and MCL demonstrating superior progression-free survival. While efficacy is well established, toxicity and relapse remain the key concerns. Costimulatory domains influence toxicity, and dual-target CAR-Ts may mitigate antigen escape."

CAR T-Cell Therapy • Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • CD22

Peripheral blast count at apheresis as a risk factor for survival following tisagenlecleucel in children and young adults (ASH 2025) - "In multivariable analysis, higher blast percentage at apheresis was not associated with an increased hazard of death (HR = 1.11, 95% CI: 0.93 - 1.33, p = 0.25). These findings suggest that the association between peripheral blasts at apheresis and inferior survival is largely influenced by disease burden at infusion, highlighting the need for further investigation into the biological and clinical significance of peripheral blasts during CAR T cell manufacturing."

Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia

Hbc-positive status for hepatis B virus does not affect CAR-T cell outcomes in lymphoma: Results from the CART-SIE study (ASH 2025) - "All HBV-positive patients received prophylactic antiviral treatment, predominantly with lamivudine (>90%)...Axi-cel was the most frequently used CAR-T product (53.5%), followed by tisa-cel (32.8%), brexu-cel (12.6%), and liso-cel (1.2%)...The lower incidence of CRS and milder ICANS severity observed in HBV-positive patients may point to potential immunomodulatory effects exerted by OBI status and/or antiviral prophylaxis. Systematic HBV screening and appropriate antiviral prophylaxis remain essential to minimize the rare risk of viral reactivation."

CAR T-Cell Therapy • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Hepatitis B • Hepatology • High-grade B-cell lymphoma • Infectious Disease • Lymphoma • Mantle Cell Lymphoma • Mediastinal B Cell Lymphoma • Non-Hodgkin’s Lymphoma • Primary Mediastinal Large B-Cell Lymphoma

Which inflammation matters? distinct risk signatures before CAR-T cell therapy and the role of inflamix (ASH 2025) - "Next, we evaluated potential differences in the use of tocilizumab, steroid therapy, and intensive care unit (ICU) hospitalization between the two groups...Overall, 65 patients (71%) received axicabtagene ciloleucel (axicel), and 27 patients (29%) received tisagenlecleucel (tisacel)...Its divergence from mEASIX and CAR-HEMATOTOX suggests that it reflects a distinct inflammatory profile. This underscores the importance of incorporating multiple biomarkers to enhance risk stratification."

CAR T-Cell Therapy • IO biomarker • Hematological Disorders • Hematological Malignancies • Inflammation • Lymphoma • Neutropenia

Real world chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma: The Australian experience (ASH 2025) - "Pts received commercial CD19-directed CAR-T cell therapy; Axicabtagene ciloleucel (Axi-cel) or Tisagenlecleucel (Tisa-cel)...Bridging therapy was administered in 70% of pts, comprising checkpoint inhibitor 10%, immunochemotherapy 20%, corticosteroids-only 10%, polatuzumab 10% and radiotherapy 20%... Eleven pts underwent leukapheresis and were eligible for analysis; with 10 pts proceeding to CAR-T infusion. The median age of the cohort was 67 years with a male predominance (89%). 50% had primary refractory disease with 80% refractory to ≥2 prior therapies."

CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • T Cell Histiocyte Rich Large B Cell Lymphoma

Recent trends in the management of relapsing/refractory diffuse large B-cell lymphoma: A systematic review of the literature (ASH 2025) - "CAR-T cell therapy with either axi-cel, liso-cel, or tisa-cel have demonstrated superior outcomes to conventional chemotherapy. Additionally, our review has outlined that the risk of adverse effects including CRS and ICANS was higher in elderly cohorts ≥75 years, in the outpatient setting, as well as when CAR-T cell initiation is delayed. Further research is warranted to evaluate the long-term outcomes of CAR-T to further optimize the management approach to patients with relapsing/refractory DLBCL."

Review • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma

Initial experience with anti-CD19 CAR-T cell therapy in patients with Relapsed/Refractory diffuse large B-cell lymphoma in a brazilian cancer center (ASH 2025) - "Tocilizumab use was similar. ICANS was more frequent with axi-cel (75%), leading to greater Anakinra use (50%), while 72% of tisa-cel patients had no ICANS... This Brazilian real-world analysis demonstrates that both CAR-T products are feasible but differ in efficacy and toxicity. Tisa-cel showed superior early responses despite higher-risk disease, while axi-cel was associated with more neurologic toxicity and early mortality. However, it is important to highlight the limitations of our data, considering the small sample size, missing follow-up registries and the heterogeneity in baseline characteristics, precluding a robust comparative analysis between products."

CAR T-Cell Therapy • Clinical • IO biomarker • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Fried's frailty phenotype predicts survival in pts with relapsed/refractory lymphoma or myeloma undergoing chimeric antigen receptor T-cell therapy – a prospective, observational Study (ASH 2025) - "Idecagtagene vicleucel and tisagenlecleucel were the most frequently administered CART products...2 non-disease related deaths were 1 death from COVID and 1 ICANS-related death from teclistamab after relapse 1 year and 2 years after infusion, respectively...Our future work aims to implement an exercise regimen to improve outcomes and to determine whether frailty is associated with adverse disease biology. Future work to uncover biologic mechanisms of frailty and adverse disease biology may identify novel targets for intervention to improve outcomes for frail pts."

CAR T-Cell Therapy • Clinical • Observational data • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Multiple Myeloma • AGT

The simple c-reactive protein (CRP) to albumin ratio (CAR) stratifies treatment response and survival following chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma (ASH 2025) - " The single institution cohort includes patients with a diagnosis of R/R NHL after ≥1 line of prior therapy treated with axicabtagene ciloleucel, brexucabtagene autoleucel, lisocabtagene maraleucel, or tisagenlecleucel. In this contemporary, large, single-institution cohort study, we show that pre-lymphodepletion CAR is associated with relapse and overall survival after adjustment for other well-established risk factors. Since CAR is a dynamic, readily available estimate of the inflammatory and nutritional state as demonstrated previously in other cancer types, these results suggest that it can also be applied to the setting of CAR T therapy for R/R NHL, in combination with pre-treatment disease burden as measured by LDH. Our results support our previous findings on the crucial role of inflammation in CAR T and cancer immunotherapy outcomes, and lend support to a rational target for therapeutic and behavior intervention."

CAR T-Cell Therapy • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • CRP

Late immune effector cell-associated hematotoxicity (ICAHT) in patients with relapsed refractory large B-cell lymphoma receiving anti-CD19 chimeric antigen receptor T-cell therapy (ASH 2025) - " We identified 139 pts who received axi-cel or tisa-cel: 113 were included in our cytopeniaanalysis; 26 excluded for early progression, death, or initiation of subsequent therapy...No association was found with age, gender, CAR product, median number of priortherapies, prior ASCT or bendamustine exposure... Late cytopenias remain persistent toxicity after CAR T-cell therapy in RR LBCL. Although, themajority of our pts recovered counts by 1 year, a notable proportion develop adverse outcomes includinglate disease progression or MDS/AML. In this report, we validated the CAR-HT score in predicting ICAHT at3 and 6 months, supporting its potential utility for resource planning and closer monitoring for thesenegative outcomes."

CAR T-Cell Therapy • Clinical • Acute Myelogenous Leukemia • B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • High-grade B-cell lymphoma • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Mediastinal B Cell Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Primary Mediastinal Large B-Cell Lymphoma • Thrombocytopenia

Comparative CRS risk across CAR-T constructs in DLBCL in real-world cohorts (ASH 2025) - "Tocilizumab was usedmore frequently in axi-cel patients compared to tisa-cel (52.6% vs 41.7%, p=0.474) and liso-cel (58.8% vs38.5%, p=0.191).Among patients with post-infusion biomarker positivity, ferritin levels were numerically higher in liso-celcompared to axi-cel (3311 vs 2417 ng/mL, p=0.726), and significantly higher in axi-cel than tisa-cel (8806vs 1551 ng/mL, p=0.216). Future studies should consider biomarkertrajectory and comorbidity burden when developing risk-adapted toxicity management strategies. Theseinsights support more nuanced post-infusion monitoring and product-specific counseling in clinicalpractice."

Clinical • IO biomarker • Real-world • Real-world evidence • B Cell Lymphoma • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Diffuse Large B Cell Lymphoma • Heart Failure • Hematological Malignancies • Lymphoma • Metabolic Disorders • Nephrology • Non-Hodgkin’s Lymphoma • Renal Disease • Type 2 Diabetes Mellitus • CRP

Large B-cell lymphoma following CD19-directed CART-cell therapy failure: Impact of CAR construct on disease features and outcomes of subsequent therapies (ASH 2025) - "Progression-Free Survival-2 (PFS2) was defined from the first post-CARTprogression to the next event (progression, new therapy, death, or last follow-up). Of 327 LBCL pts treated with CART19 (01/2018–12/2024), 77% (N=251) received a 4-1BB-basedproduct (tisa-cel N=181; liso-cel N=70) and 23% (N=76) the CD28-based axi-cel...Baseline characteristics were similar between CART costimulationgroups, though pts receiving CD28-based CART were younger (56 vs. 66 yrs; p<0.01), more often receivedfludarabine/cyclophosphamide lymphodepletion, and treated more frequently in 2nd line...Polatuzumab-basedtherapies achieved the longest median PFS2 at 7.6 months (bispecific 3.9, lenalidomide 2.7, local 3.1,targeted 4.2, other 2.3 months)... In this study of LBCL pts relapsing after CART19, PFS2 was overall short for both 4-1BB andCD28 CART19. CD19-negative relapses and CIITA mutations were more frequent after axi-cel.Polatuzumab-based regimens achieved the longest PFS2. Ongoing analyses..."

CAR T-Cell Therapy • IO biomarker • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • CD19 • CIITA • CREBBP • KMT2D • PD-L1 • PIK3C2B • TP53